BUZZ-Coherus Oncology tumbles on planned equity offering

Reuters02-13
BUZZ-Coherus Oncology tumbles on planned equity offering

** Coherus Oncology CHRS.O shares down 15% post-market at $1.73 as it looks to raise equity

** Redwood City, California-based firm announces stock offering without disclosing deal size

** It intends to use net offering proceeds to support ongoing commercialization of LOQTORZI (toripalimab-tpzi), its FDA-approved immunotherapy to treat adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, a rare type of head and neck cancer, and clinical development of product candidates

** TD Cowen, Guggenheim and Oppenheimer joint bookrunners

** Co has ~120.9 mln shares outstanding for about $240 mln market cap

** Stock on Thurs ended down 3 cents at $2.01. It's up ~42% YTD and has roughly doubled over the past six months

** 5 of 6 analysts rate the stock "strong buy" or "buy", 1 "hold"; median PT $6, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment